XLRN News and Press, Acceleron Pharma Inc. From 06/11/21

Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the first data from the Phase 2 BEYOND study evaluating Reblozyl ® (luspatercept-aamt), a first-in-class erythroid maturation agent, plus best supportive care in adult patients...

Results showed treatment with Reblozyl plus best supportive care improved anemia in 77% of patients compared to placebo Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-we...

- Event to be webcast on Tuesday, June 22 at 8:00 a.m. EDT - Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced...

Acceleron Pharma (XLRN) presents preliminary interim data from the SPECTRA Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension ((PAH)).The trial shows that sotatercept-treated patients  experienced improvements in multiple key hemodynamic measures. In this study...

Acceleron Pharma (XLRN) announces interim results from the open-label extension of the PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension ((PAH)). The investigators observed maintained or enhanced responses with sotatercept treatment in multiple study endpoin...

– Treatment with sotatercept in the ongoing SPECTRA Phase 2 trial was associated with improvements in resting and exercise hemodynamics at week 24 – – Sotatercept was generally well tolerated, consistent with the previously reported safety profile in PAH a...

- Data presented show maintained or improved responses in multiple efficacy endpoints among patients treated with sotatercept plus stable background therapy for up to 48 weeks - - Patients receiving placebo plus stable background therapy during the 24-week placebo-controlled p...

- Results from the BEYOND Phase 2 trial in non-transfusion dependent beta-thalassemia to be presented during Presidential Symposium – - Additional presentations to feature data from longer-term use of REBLOZYL in populations of patients with beta-thalassemia, myelodyspl...

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a conference call and webcast on Wednesday, May 19, 2021 at...

The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Acceleron Pharma Inc. 2021 Q1 - Results - Earnings Call Presentation